Day 1 – Tuesday, February 25th
08:00-08:15 Opening Welcome and Introduction
Claudio Cerchione, Italy; Hagop Kantarjian, USA; Giovanni Martinelli, Italy
08:15-09:55 Session 1: Multiple Myeloma – Biology
Chairs: Cirino Botta, Italy, Bruno Paiva, Spain
From research to the clinical practice: the milestones of myeloma biology
Alessandra Romano, Italy
Targeting the bone marrow microenvironment in multiple myeloma
Cirino Botta, Italy
Unmasking novel biomarkers to sketch future trajectories in multiple myeloma therapy
Vanessa DeSantis, Italy
Adhesion molecule interactions at the multiple myeloma interface: new insights
Antonio Solimando, Italy
How and when to integrate flow cytometry in daily practice of multiple myeloma
Bruno Paiva, Spain
How to modulate immune system in mutiple myeloma?
Annamaria Gullà, Italy
09:55-10:10 Coffee Break
10:10-11:35 Session 2: Multiple Myeloma – Clinical Session
Chairs: Claudio Cerchione, Italy, Hans Carl Lee, USA
How I manage smoldering multiple myeloma
Maria Victoria Mateos, Spain
Multiple myeloma: State-of-the-art in Europe
Claudio Cerchione, Italy
Multiple myeloma: State-of-the-art in the USA
Hans Carl Lee, USA
Multiple myeloma cured in 2030: what are the next steps?
Kenneth Anderson,
USA
Is it time for biomarkers-driven approach in smoldering and multiple myeloma?
Irene Ghobrial, USA
11:35-12:45 Session 3: Multiple Myeloma – Front-line Setting
Chairs: Claudio Cerchione, Italy; Angelo Maiolino, Brazil; Vittorio Montefusco, Italy
How I manage multiple myeloma in frontline setting
Vittorio Montefusco
, Italy
New insights and opportunities: autologous SCT as backbone in induction therapy or bispecific/CAR-T?
Angelo Maiolino, Brazil
How I manage extramedullary disease and plasma cell leukemia
Daniele Derudas, Italy
How I manage bone disease and its complications in multiple myeloma
Evangelos Terpos, Greece
12:45-13:00 Break – Lunch Box Pick-up
13:00-14:00 New perspectives for RRMM TCR patients
Industry-supported Lunch Symposium
by Oncopeptides
Prof. Claudio Cerchione: Melflufen, mechanism of action and data from clinical trials
Dott. Vittorio Montefusco: Therapeutic options in patients not eligible for immunotherapy
Prof.ssa. Alessandra Romano: Clinical cases in real world practice
Prof. Paul Richardson: Past, present and future of PDC
Discussion
14:00-14:10 Short Break
14:10-15:35 Session 4: Multiple Myeloma – Relapsed/refractory
Chairs: Francesco Di Raimondo, Italy; Renato Zambello, Italy
How to manage early relapses
Bispecific antibodies, ADC and CAR-Ts: Joshua Richter, USA
Other options: Alessandra Romano, Italy
How to manage heavily pretreated RRMM
Francesco Di Raimondo,
Italy
Mechanisms of disease resistance to T-cell based therapies: a clinical perspective
Paul Richardson, USA
Determinants of Resistance to CAR-T and T-cell engagers in multiple myeloma
Paola Neri, Canada
15:35-16:50 Session 5: Chronic Lymphocytic Leukemia
Chairs: Antonio Cuneo, Italy; Alessandra Ferrajoli, USA; Gianluca Gaidano, Italy; Ahmad Ibrahim, Lebanon
How I manage CLL
At MDACC: Alessandra Ferrajoli, USA
In Italy: Antonio Cuneo, Italy
Which current sequencing in CLL in the real world?
Gianluca Gaidano, Italy
How to use novel agents in elderly CLL
Ahmad Ibrahim, Lebanon
What prognostic models should we use in CLL?
Stefano Molica, Italy
16:50-17:45 Session 6: Hodgkin and T-Cell Lymphomas: State-of-the-art
Chairs: Amanda Cashen, USA; Carmino De Souza, Brazil; Adrián Mosquera, Spain
How I manage Hodgkin in Disease in the USA
Amanda Cashen, USA
Advanced-stage Hodgkin lymphoma: the end of ABVD and BEACOPP?
Carmino De Souza, Brazil
Decision support systems: a new paradigm in medical information
Adrián Mosquera, Spain
17:45-19:30 Session 7: Non-Hodgkin Lymphomas: State-of-the-art
Chairs: Andrés Ferreri, Italy; Stefano Luminari, Italy; Gerardo Musuraca, Italy
How I manage follicular lymphoma
Stefano Luminari, Italy
How I manage marginal zone lymphoma
Luca Arcaini, Italy
Current and future therapeutic approach in first line in DLBCL
Umberto Vitolo, Italy
How I manage RR in DLBCL
Gerardo Musuraca, Italy
How I manage CNS lymphomas
Andrés Ferreri, Italy
How I manage aggressive lymphomas in elderly patients
Raúl Córdoba, Spain
How to integrate academic CAR-T in daily treatment of hematologic malignancies
Julio Delgado, Spain
19:30-20:45 Session 8: Allogenic SCT in Hematological Malignancies: Dead, or Alive and Kicking?
Chairs: Massimo Dominici, Italy; Jean El Cheikh, Lebanon; Filippo Milano, USA; Arnon Nagler, Israel
Towards the future
CAR-T as standard of care: Nitin Jain, USA
Allogenic SCT as standard of care: Arnon Nagler, Israel
New conditioning regimen pre-allogenic SCT in hematologic malignancies
Jean El Cheikh, Lebanon
Life after CAR-T
Jose Maria Ribera, Spain
How to develop an innovative cellular therapies center: from clinical trials to real-world data
Filippo Milano, USA
20:45 Conclusions Day 1
Claudio Cerchione, Italy, Giovanni Martinelli, Italy
Day 2 – Wednesday, February 26th
08:00-08:20 Welcome to Day 2
Claudio Cerchione, Italy, Giovanni Martinelli, Italy
08:20-09:20 Session 9: CAR-T and Cellular Therapies in Hematological Malignancies: From Dream to Reality
Chairs: Giuliano Bolondi, Italy; Julio Delgado, Spain; Massimiliano Mazza, Italy
From the preclinical to the production stage: a CAR for T-cell malignancies
Massimiliano Mazza, Italy
Balancing efficacy and toxicity in CAR-T and bispecific antibodies-based therapies: the point of view from the reanimation room
Giuliano Bolondi, Italy
CAR-T– from research to clinical applications
In solid tumors: Massimo Dominici, Italy
In hematology: Franco Locatelli, Italy
09:20-10:15 Session 10: Acute Lymphoblastic Leukemia – Clinical Session
Chairs: Claudio Cerchione, Italy; Giovanni Martinelli, Italy
How I manage ALL at MDACC
Hagop Kantarjian, USA
How I manage Elderly ALL at MDACC
Elias Jabbour, USA
How I manage ALL in Europe
Giovanni Martinelli, Italy
10:15-10:35 Coffee Break
10:35-12:00 Session 11: Acute Myeloid Leukemia – State-of-the-art
Chairs: Claudio Cerchione, Italy; Giovanni Martinelli, Italy
How I manage AML at the MDACC
Hagop Kantarjian, USA
Non-Intensive treatment of elderly/unfit patients with AML at MDACC
Tapan Kadia, USA
Past, present and future of FLT3 inhibitors in AML: moving towards cure
Giovanni Martinelli, Italy
How I manage IDH-mutated AML at MDACC
Courtney DiNardo, USA
TP53 mutated AML – where are we?
Naval Daver, USA
12:00-13:10 Session 12: Acute Myeloid Leukemia – Special Entities
Chairs: Brunangelo Falini, Italy; Giovanni Martinelli, Italy
Is all oral therapy of AML a reality for the future?
Farhad Ravandi, USA
How I manage secondary AML
Alessandro Isidori, Italy
Targeted therapy of NPM1-mutated AML
Brunangelo Falini, Italy
TP53 in myeloid leukemias: targeting the guardian of the genome
Michael Andreeff, USA
13:10-13:40 Lunch Break
13:40-15:00 Session 13: Acute Myeloid Leukemia – Clinical Session
Chairs: Sara Galimberti, Italy; Mauricette Michallet, France
How I manage BPDCN
Naveen Pemmaraju, USA
The pathogenesis of acute leukemias: approaches and molecular insights
Ilaria Iacobucci, USA
Digital droplet PCR in hematologic malignancies: a new useful molecular tool
Sara Galimberti, Italy
Therapy-related AML: CHIP documentation in cancer, new perspectives in prognosis and treatment
Mauricette Michallet, France
15:00-15:15 Special lecture: Role of AI in Diagnostics
Torsten Haferlach, Germany
15:15-15:30 SOHO Insights Roundtable: Acute Myeloid and Lymphoblastic Leukemia
Nicola Stefano Fracchiolla, Italy; Michele Gottardi, Italy; Carmelo Gurnari, Italy; Francesco Lanza, Italy; Federico Lussana, Italy; Agostino Tafuri, Italy; Calogero Vetro, Italy; Daniele Vallisa, Italy
15:30-16:25 Session 14: Myeloproliferative Neoplasms – State-of-the-art
Chairs: Hanan Hamed, Egypt; Alessandro Lucchesi, Italy; Tariq Mughal, UK
Novel combination and JAK and non-JAK inhibitor therapies on the horizon
Tariq Mughal, UK
Neutrophilia other than CML
Hanan Hamed, Egypt
A new pathogenetic paradigm for MPN: the “circulating wound”
Alessandro Lucchesi, Italy
16:25-17:10 Session 15: Chronic Myeloid Leukemia – State-of-the-art
Chairs: Claudio Cerchione, Italy; Carlo Gambacorti-Passerini, Italy
How I manage CML at MDACC
Elias Jabbour, USA
CML history: the transition from interferon to TKI therapy
Carlo Gambacorti-Passerini, Italy
Stopping therapy (TFR) from clinical trials to real world – which patients, when and how to monitor
Gianantonio Rosti, Italy
17:10-17:25 SOHO Insights Roundtable – CML and MPN
Massimo Breccia, Italy; Paola Guglielmelli, Italy; Nicola Polverelli, Italy
17:25-18:25 Session 16: Myelodysplastic Syndromes – State-of-the-art
Chairs: Esther Oliva, Italy; Matteo Della Porta, Italy; Phillip Scheinberg, USA
Progress in medical therapy in aplastic anemia: why it took so long?
Phillip Scheinberg, USA
A practical approach to molecular pathology of myelodysplastic syndromes
Matteo Della Porta, Italy
How I treat lower-risk myelodysplastic syndromes
Esther Oliva, Italy
Is a personalized treatment approach possible for myelodysplastic syndromes: when is the optimal time for a transplant?
Elena Crisà, Italy
18:25-18:40 SOHO Insights Roundtable – Myelodysplastic Syndromes
Carlo Finelli, Italy
18:40-19:55 Session 17: Spotlights on Rare Entities and Non-Malignant Diseases
Chairs: Domenico Girelli, Italy; Valeh Huseynov, Azerbaijan; Hans Carl Lee, USA; Arcangelo Liso, Italy
How I manage Waldenstrom’s Macroglobulinemia in the era of novel agents
Steven Treon, USA
How I manage AL amyloidosis at MDACC
Hans Carl Lee, USA
How I manage advanced systemic mastocytosis
Daniela Cilloni, Italy
New Insights in iron deficiency anemia
Domenico Girelli, Italy
New insights in transfusion medicine
Valeh Huseynov, Azerbaijan
19:55-20:10 SOHO Insights Roundtable – Rare Entities and Non-Malignant Diseases
Arcangelo Liso, Italy; Alessandra Romano, Italy
20:10 Conclusions. See You Next Year
Claudio Cerchione, Italy; Giovanni Martinelli, Italy